Wicab

The company’s flagship product, the BrainPort Vision Pro/V100, has received FDA clearance as an adjunctive electronic vision aid for profoundly blind individuals. Clinical studies have demonstrated usability and improvements in orientation and mobility. The company also markets the BrainPort Balance Plus device for balance rehabilitation; both leverage proprietary sensory substitution via tongue-based electro-tactile feedback.\n\nU.S. Department of Defense funded a trial in traumatic brain injury patients; U.S. Veterans Administration has begun purchasing devices.\n\nDevices are available commercially in select regions including China and Canada; efforts to reintroduce to USA/EU ongoing as of late 2022.\n\nNo direct competitors with similar approved devices currently on the market.\n\nOver $5 million in NIH grants since inception; total funding raised exceeds $7 million from investors including Google and Haiyin Capital.\n\nEstimated annual revenue ranges from $2–10 million with approximately a dozen employees as of recent reports.\n\nKey challenge remains reimbursement/access due to high cost relative to target population’s resources.